Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;59(2):111-114.
doi: 10.5114/reum.2021.103394. Epub 2021 Feb 9.

Takayasu's arteritis occurring under TNF blockers in a patient with spondyloarthritis: is it an association or a paradoxical effect?

Amel Rezgui  1 , Maissa Thabet  1 , Sahar Makki  1 , Jihed Anoun  1 , Imen Ben Hassine  1 , Monia Karmeni  1 , Fatma Ben Fredj  1 , Anis Mzabi  1 , Chedia Laouani  1
Affiliations
Review

Takayasu's arteritis occurring under TNF blockers in a patient with spondyloarthritis: is it an association or a paradoxical effect?

Amel Rezgui et al. Reumatologia. 2021.

Abstract

Coexistence of spondyloarthritis (SpA) and Takayasu's arteritis is not a common finding, but such cases have been discussed, particularly in the context of choice of therapy. Inhibition of inflammation by tumor necrosis factor inhibitors (TNFi) is a key aspect of the treatment of SpA and also positive effects of such treatment in concomitant large vessel vasculitis have been reported. However, TNFi is also associated with the possibility of initiating vasculitis. The present article based on a case study and the available literature is an attempt to discuss coexistence of these two diseases and the impact of treatment with biological drugs from the anti-TNF group in the course of SpA with Takayasu's arteritis.

Keywords: Takayasu’s arteritis; ankylosing spondylitis; tumor necrosis factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Thoracic angio-CT showing right subclavian artery stenoses.
Fig. 2
Fig. 2
Abdominal angio-CT showing superior mesenteric and renal arteries stenoses.
See this image and copyright information in PMC

References

    1. Rivière E, Arnaud L, Ebbo M, et al. Takayasu arteritis and spondyloarthritis: coincidence or association? A study of 14 cases. J Rheumatol. 2017;44:1011–1017. doi: 10.3899/jrheum.160762. - DOI - PubMed
    1. Ben Abdelghani K, Fazaa A, Ben Abdelghani, et al. Chronic inflammatory rheumatism associated with Takayasu disease. Ann Vasc Surg. 2013;27:353.e1–6. doi: 10.1016/j.avsg.2011.11.048. - DOI - PubMed
    1. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev. 2012;11:678–684. doi: 10.1016/j.autrev.2011.11.025. - DOI - PubMed
    1. Youngstein T, Peters JE, Hamdulay SS, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S11–18. - PubMed
    1. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014;26:7–15. doi: 10.1097/BOR.0000000000000004. - DOI - PubMed